Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19
“COVID-19 has exposed crucial vulnerabilities in medical supply chains, and today’s production can’t keep up with clinical innovation, medical discovery, and the need to quickly produce and distribute seriously important drugs at scale.”It is critical that we adopt solutions that will safeguard the manufacturing supply chain, and supply more certainty around drug advancement and the capability to scale up the production of safe, reliable but also more intricate products that science is making possible,” said Dr. Gottlieb, in a declaration. “RESILIENCE will allow these options by combining cutting edge innovation, an unequaled swimming pool of talent, and the industry’s first shared service organization design.